PMA device
Deflux Injectable Gel
Palette Life Sciences · Agent, Bulking, Injectable For Gastro-Urology Use (LNM, Class III) · First FDA decision Sep 24, 2001, newest Feb 23, 2016Overactive bladder and urinary incontinence
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
9
PMA pathway
Device trials
4
Naming "Deflux"
MAUDE reports
197
Brand "Deflux", since 2015
PubMed studies
229
Mentioning "Deflux"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Deflux Injectable Gel
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 9 decisions filed under this name.
- DEFLUX INJECTABLE GELPMA supplement
P000029-S080 · Decided Feb 23, 2016 · 357 days after receipt · Normal 180 Day Track No User Fee
Device type: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE (LNM) · GI, Urology & Nephrology
- DEFLUX INJECTABLE GELPMA supplement
P000029-S075 · Decided Oct 17, 2013 · 90 days after receipt · Normal 180 Day Track
Device type: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE (LNM) · GI, Urology & Nephrology
- DEFLUX INJECTABLE GELPMA supplement
P000029-S067 · Decided Oct 26, 2010 · 239 days after receipt · Normal 180 Day Track
Device type: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE (LNM) · GI, Urology & Nephrology
3 more FDA decisions with a free account
Older decisions: P000029-S017, P000029-S012, P000029
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Deflux", any status and sponsor, newest update first.
- Trial of NASHA Dx Urethral Bulking SystemPivotal-lookingNot yet recruiting
Palette Life Sciences, Inc.Not on our public-company list
NCT07850804 · 314 participants (planned) · Start Sep 2026 · Primary completion Sep 2027
Device: NASHA Dx; Bulkamid · For: Urinary Incontinence; Urinary Incontinence (UI); Urinary Incontinence , Stress and 4 more
Sites: Tustin, California; Lincoln, Nebraska; Charlotte, North Carolina · 5 sites in all
Galderma R&DNot on our public-company list
NCT01110681 · 115 participants · Start Nov 2007 · Primary completion Nov 2009
Device: Solesta (Dextranomer in gel of stabilized non-animal hyaluronate) · For: Fecal Incontinence
Sites: Vancouver, Canada; HUS, Finland; Nantes, France · 15 sites in all
South Shore HospitalAcademic, hospital or other
NCT00706329 · 25 participants · Start Apr 2008 · Primary completion Mar 2009
Device: Deflux · For: Umbilical Hernia
Sites: South Weymouth, Massachusetts
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Deflux", and for the whole product code for context.
This brand
197 reports: 126 malfunction, 70 injury, 1 death
Whole product code LNM
544 reports: 170 malfunction, 369 injury, 2 death
Newest reports for this brand
- JP DEFLUX SYRINGE (1ML)Malfunction
3014909464-2026-00118 · Received Oct 27, 2026 · Event dated Oct 1, 2026
Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Device problem as coded: Break
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- JP DEFLUX SYRINGE (1ML)Malfunction
3014909464-2026-00111 · Received Oct 23, 2026 · Event dated Sep 25, 2026
Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Device problem as coded: Break
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- EU DEFLUX SYRINGE (1ML)Malfunction
3014909464-2026-00117 · Received Oct 22, 2026 · Event dated Sep 17, 2026
Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Device problem as coded: Break
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Deflux"[tiab]. The summary above synthesizes these.
- Deflux® Endoscopic Treatment of Vesicoureteral Reflux (VUR) in Japan.
Front Pediatr · 2022
- Endoscopic injection therapy.
Kim SW, Lee YS, Han SW · Investig Clin Urol · 2017Review
- The Effectiveness of Deflux® Treatment for Vesicoureteral Reflux Following Pediatric Renal Transplantation: A Single-Institution Challenging Experience.
Obata S, Nagata K, Suematsu S, et al. · J Pediatr Surg · 2024
- Ureteral reimplantation after deflux failure for vesicoureteral reflux in renal transplant.
Morelli M, Boissier R, Tadrist A, et al. · World J Urol · 2022
- Deflux for vesicoureteral reflux: pro--the case for endoscopic correction.
Canning DA · Urology · 2006Editorial, Review
- Unraveling the Veil: Deflux Injection Masquerading as Calculus at the Vesicoureteric Junction.
Dasan JK, Augustine A, Singh JC, et al. · Indian J Radiol Imaging · 2024
- Vantris vs. deflux for treatment of paediatric vesicoureteral reflux: Efficacy and obstruction risk.
Renaux-Petel M, Grynberg L, Lubet A, et al. · Fr J Urol · 2024Comparative Study
- Pediatric urolithiasis.
Mandeville JA, Nelson CP · Curr Opin Urol · 2009Review
- A systematic review of outcomes of Deflux® treatment for vesicoureteral reflux following pediatric renal transplantation.
Rebullar K, O'Kelly F, Koyle MA, et al. · J Pediatr Urol · 2021Systematic Review
- Distal Ureteral Calculus or Deflux Calcification?
Spencer E, Baber J, Ferretti M · J Endourol Case Rep · 2019Case Reports
- Endoscopic treatment with Deflux for refluxing duplex systems.
Rossini CJ, Moriarty KP, Courtney RA, et al. · J Laparoendosc Adv Surg Tech A · 2009
- Successful rescue pneumovesicoscopic surgery for post-Deflux® vesicoureteral junction obstruction.
Yang LY, Chou CM, Huang SY, et al. · Pediatr Surg Int · 2023
Other devices of this type
Also filed under product code LNM.
- Macroplastique ImplantsUroplasty, LLC · PMA 2023
- Solesta (Injectable Gel)Palette Life Sciences · PMA 2021
- Durasphere Injectable Bulking AgentCarbon Medical Technologies, Inc. · PMA 2026
- Coaptite Injectable ImplantMerz North America, Inc. · PMA 2024
- Contigen Bard Collagen ImplantAllergan, Inc. · PMA 2009
- Bard Tegress Urethral ImplantC.R. Bard, Inc. · PMA 2006
- Enteryx Procedure KitBoston Scientific Corp · PMA 2005
- Durasphere ExpCarbon Medical Technologies, Inc. · PMA 2004
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.